Vigil Neuroscience, Inc. (NasdaqGM: VIGL)
Health Care · Biotechnology · US
$—
— today · — 1Y
Vigil Neuroscience, Inc. (NasdaqGM: VIGL) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores Vigil Neuroscience, Inc. across four factors: quality 26/100. Its strongest factor is quality.
VIGL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.10
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 69
- Next earnings
- —
About Vigil Neuroscience, Inc.
Vigil Neuroscience, Inc., founded in 2020 and headquartered in Cambridge, Massachusetts, is a biotechnology company concentrating on microglia to develop transformative treatments for neurodegenerative diseases. The firm aims to provide disease-altering therapies for patients, their families, and caregivers affected by both rare and widespread neurological disorders. The company's primary experimental therapy is VGL101, a fully human monoclonal antibody (mAb). This compound is engineered to activate the triggering receptor expressed on myeloid cells 2 (TREM2) and is currently in Phase I clinical trials. VGL101 is being investigated for its potential in treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), cerebral adrenoleukodystrophy, and Alzheimer's disease. Furthermore, Vigil Neuroscience is also advancing an orally administered small molecule designed to act as a TREM2 agonist. This alternative therapeutic approach targets common neurodegenerative conditions associated with impaired microglial function.
- Founded
- 2020
- Listed since
- Jan 7, 2022
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.62 | -1.69% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.